ATE412769T1 - Nadh-oxidase als zielmolekül in diagnose und therapie - Google Patents

Nadh-oxidase als zielmolekül in diagnose und therapie

Info

Publication number
ATE412769T1
ATE412769T1 AT95918829T AT95918829T ATE412769T1 AT E412769 T1 ATE412769 T1 AT E412769T1 AT 95918829 T AT95918829 T AT 95918829T AT 95918829 T AT95918829 T AT 95918829T AT E412769 T1 ATE412769 T1 AT E412769T1
Authority
AT
Austria
Prior art keywords
nadh oxidase
cells
therapy
inhibitors
normal
Prior art date
Application number
AT95918829T
Other languages
English (en)
Inventor
D Morre
Stephen BYRN
Frederick Crane
Dorothy Morre
Original Assignee
Morre D James
Morre Dorothy M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/222,799 external-priority patent/US5605810A/en
Priority claimed from US08/248,084 external-priority patent/US5569673A/en
Application filed by Morre D James, Morre Dorothy M filed Critical Morre D James
Application granted granted Critical
Publication of ATE412769T1 publication Critical patent/ATE412769T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95918829T 1994-04-05 1995-04-04 Nadh-oxidase als zielmolekül in diagnose und therapie ATE412769T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/222,799 US5605810A (en) 1994-04-05 1994-04-05 NADH oxidase assay for neoplasia determination
US08/248,084 US5569673A (en) 1994-05-24 1994-05-24 Capsacinoid compounds as proliferation inhibitors

Publications (1)

Publication Number Publication Date
ATE412769T1 true ATE412769T1 (de) 2008-11-15

Family

ID=26917153

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95918829T ATE412769T1 (de) 1994-04-05 1995-04-04 Nadh-oxidase als zielmolekül in diagnose und therapie

Country Status (7)

Country Link
EP (1) EP0752872B1 (de)
JP (1) JPH10503921A (de)
AT (1) ATE412769T1 (de)
AU (1) AU701529B2 (de)
CA (1) CA2187200A1 (de)
DE (1) DE69535876D1 (de)
WO (1) WO1995026743A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6875575B1 (en) 1998-11-25 2005-04-05 Osi Pharmaceuticals, Inc. Diagnostic methods for neoplasia
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US7053188B2 (en) 2002-02-22 2006-05-30 Purdue Research Foundation Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US7491413B2 (en) 2005-09-30 2009-02-17 Purdue Research Foundation Compositions and methods for treating and preventing virus infections
US20120015390A1 (en) 2009-03-27 2012-01-19 Protea Biopharma N.V. Methods for the Detection and Treatment of Aberrant Prion Disease
CN120668619A (zh) * 2025-06-06 2025-09-19 苏州卫生职业技术学院 一种用于药物筛选的荧光探针材料及药物筛选方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US4952394A (en) * 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
WO1990003185A1 (en) * 1988-09-28 1990-04-05 Ideon Corporation Combination enzyme immunotherapeutics

Also Published As

Publication number Publication date
EP0752872B1 (de) 2008-10-29
EP0752872A4 (de) 2005-01-19
CA2187200A1 (en) 1995-10-12
DE69535876D1 (de) 2008-12-11
JPH10503921A (ja) 1998-04-14
WO1995026743A1 (en) 1995-10-12
AU701529B2 (en) 1999-01-28
EP0752872A1 (de) 1997-01-15
AU2459995A (en) 1995-10-23

Similar Documents

Publication Publication Date Title
ATE412769T1 (de) Nadh-oxidase als zielmolekül in diagnose und therapie
Bourrié et al. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
Pereira et al. Involvement of oxidative stress on the impairment of energy metabolism induced by Aβ peptides on PC12 cells: protection by antioxidants
JP4451930B2 (ja) 一酸化窒素の生成を阻害するテトラサイクリン化合物の使用方法
PT645142E (pt) Nova substancia fisiologicamente activa
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
Djeu et al. Selective growth of natural cytotoxic but not natural killer effector cells in interleukin-3
Ronald et al. Failure of urinary beta-glucuronidase activity to localize the site of urinary tract infection
Boulton et al. Effect of L-dopa therapy on urinary p-tyramine excretion and EEG changes in Parkinson's disease
EP2357223A3 (de) Humane Stammzellen und Verfahren zur Verwendung
Takeichi et al. Inducible nitric oxide synthase activity by interferon‐g‐producing cells in human radicular cysts
Sawada et al. Favorable response to lymphoblastoid interferon-alpha in children with chronic hepatitis C
Glackin et al. E. Cystic fibrosis
Finkel et al. Fluorometric and microbiological assays for rifampicin and the determination of serum levels in the dog
BR9707776A (pt) Utilização da il-7 no tratamento das doenças autoimunes em especial o diabetes mellitus dependente de insulina
Kirshen et al. Comparison of urinary and serum amylase values following pancreatic stimulation in patients with and without pancreatic disease
Isildar et al. DNA damage in intact cells induced by bacterial metabolites of chloramphenicol
Marino et al. Bacteremic pneumococcal pneumonia and myoglobinuric renal failure
Brazzelli et al. Hepatitis C infection in Italian psoriatic patients: prevalence and correlation with patient age and psoriasis severity.
Matsumoto et al. Application of photocrosslinkable poly (vinyl alcohol) to enzyme membranes for biosensors
Forbes et al. Loss of receptor activity for mouse erythrocytes precedes tumour promoter-induced maturation of chronic lymphocytic leukaemia cells
RU94005362A (ru) Способ лабораторной диагностики дифтерийной инфекции у детей
Khokhani et al. Comparative study of tinidazole and metronidazole in amoebic liver abscess
RU94008771A (ru) Способ прогнозирования продолжительности жизни онкологических больных 4-ой стадии заболевания после диагностических хирургических вмешательств
RU2000101938A (ru) Способ определения патогенности энтеровирусных штаммов, выделенных от детей, больных различными формами нейроинфекций

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties